Pharmacogenetics - Tailoring treatment for the outliers

New England Journal of Medicine

Volumn 360, Issue 8, 2009, Pages 811-813

  Woodcock, Janet ^a   Lesko, Lawrence J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CARBAMAZEPINE; CLOPIDOGREL; CODEINE; MERCAPTOPURINE; TAMOXIFEN; WARFARIN;

ACUTE CORONARY SYNDROME; ALGORITHM; BREAST CANCER; CLINICAL PRACTICE; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG RESPONSE; EDITORIAL; GENETIC RISK; GENETIC SCREENING; HUMAN; INTERNATIONAL NORMALIZED RATIO; LEUKOPENIA; MAINTENANCE DRUG DOSE; PHARMACOGENETICS; PREDICTOR VARIABLE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE;

EID: 60849115571     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe0810630     Document Type: Editorial

References (5)

1. The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacoge-netic data. N Engl J Med 2009;360:753-64.
2. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-meth-lytransferase gene locus. J Natl Cancer Inst 1999;91:2001-8.
3. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62.
4. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-79.
5. Food and Drug Administration. Information on carbamaze-pine (marketed as Carbatrol, Equetro, Tegretol, and generics). (Accessed January 30, 2009, at http://www.fda.gov/cder/drug/infopage/carbamazepine/default.htm.)